Zinc Supplement in Regorafenib Treated mCRC Patient
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Phase II randomized trial to investigate whether supplementation of zinc decreases the
incidence of HFSR that occurs after treatment of tyrosine kinase inhibitor, regorafenib.